A Dosing Study of Intravitreal Bevacizumab for Retinopathy o... | Clinical Trial | StuddyBuddy@endsection A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05712642

A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

Conditions: Retinopathy of Prematurity

Sex: All
Ages: 28 Weeks – 40 Weeks
Phase: PHASE3
Enrollment: 19
Sponsor: Cairo University

Location: Egypt

Summary

The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :Serum Systemic VEGF levels. Retinal Vascularization.

Eligibility Criteria

Inclusion Criteria:Infants with Type 1 ROP according to ETROP study which is defined as:Zone I ROP with plus diseaseZone I, stage 3 ROP without plus diseaseZone II, stage 2 or 3 ROP with plus diseaseExclusion Criteria:Eyes with previous intravitreal injectionEyes with previous laser therapyEyes with any other intraocular pathology other than ROP (congenital cataract, congenital glaucoma, any retinal pathology other than ROP)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05712642). StuddyBuddy aggregates publicly available trial information.